Aytu BioScience AYTU 深 沪
已收盘 08-29 16:00:00 美东时间
2.35
+0.040
+1.73%
华盛通- 最 高2.43
- 今 开2.35
- 成交量 6.56万股
- 最 低 2.25
- 昨 收 2.31
- 总市值 2109.57万
- 52周最高 2.85
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 0.95
- 委 比 62.96%
- 总股本 897.69万
- 历史最高 12920.00
- 量 比 0.85
- 振 幅 7.79%
- 历史最低 0.95
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aytu BioPharma Transfers Rights To AR101 Back To EnzCo, Ending Development And Terminating Rumpus Agreement With No Further Obligations
As previously disclosed in its United States Securities and Exchange Commission filings, Aytu BioPharma, Inc. (the "Company") suspended its clinical development of AR101. In connection with this suspension, the Company
08-08 05:51
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Lake Street Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $8
Lake Street analyst Thomas Flaten initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price Target of $8.
07-01 22:47
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
Aytu BioPharma Expands And Extends Lending Agreement With Eclipse Business Capital, Providing Added Working Capital Flexibility As Aytu Prepares For Commercial Launch Of EXXUA Extended-Release Tablets
Term loan maturity extended by 12 months to June 2029Principal balance on term loan expanded to $13.0 million from $11.1 million currentlyExpanded revolving line of credit facility by $1.5 millionExpanded facilities
06-23 20:14
Aytu BioPharma Closes $16.6M Stock Offering for EXXUA
Aytu BioScience ( ($AYTU) ) has provided an announcement. On June 9, 2025, Aytu...
06-10 05:07
Aytu BioPharma Enters Exclusive Agreement With Fabre-Kramer Pharmaceuticals To Commercialize First-In-Class Antidepressant EXXUA Extended-Release Tablets In The U.S.
Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD.EXXUA has demonstrated
06-06 20:07
Aytu BioPharma shares are trading higher after the company reported Q3 financial results and beat its EPS and revenue estimates.
Aytu BioPharma shares are trading higher after the company reported Q3 financia...
05-15 04:16
Earnings Scheduled For May 14, 2025
Companies Reporting Before The Bell • Cellebrite DI (NASDAQ:CLBT) is expected t...
05-14 16:32
Aytu BioPharma Proposes Settlement in Shareholder Lawsuit
Aytu BioScience ( ($AYTU) ) has issued an announcement. Aytu BioPharma, Inc. an...
2024-12-04 19:32
